A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with
immunotherapy with ipilimumab and nivolumab for up to two years. SBRT will be given in three
doses of 15Gy each to 1-5 separate metastases. Ipilimumab will be given at 1mg/kg q 6 weeks
for 12 doses, and nivolumab will be given 360mg every 3 weeks for 2-3 years.
Phase:
Phase 2
Details
Lead Sponsor:
California Pacific Medical Center Research Institute